Aimmune Therapeutics (AIMT) Gains a Briefing Docs Seen as 'Fairly Benign'
Tweet Send to a Friend
Aimmune Therapeutics (NASDAQ: AIMT) gains 10% early following FDA briefing documents. An analyst at Baird called ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
